MEDRAD, INC. announced the manufacture and delivery of the 10,000th Mark V ProVis(R) Angiography Injection System, which is used worldwide for live imaging during therapeutic interventions and diagnostic angiography procedures.
The Mark V ProVis debuted in 1999 as the heir to the successful “Mark” line of angiography injectors dating back to MEDRAD’s founding in 1964. Continuing a long tradition of consistent performance, Mark V ProVis is widely recognized as one of the most reliable injection platforms, delivering a historical average up-time of 99.9%. It also provides industry-leading flexibility with multiple system and syringe configurations and a mechanical stop to ensure patient safety by physically limiting an injection to the selected volume.
“The Mark line of Angiography injectors established MEDRAD’s reputation for reliability, and the Mark V ProVis has carried that reputation to the extreme,” said Kraig McEwen, senior vice president, MEDRAD Cardiovascular Business Unit. “Demand for Mark V ProVis has been remarkably consistent in cardiology, interventional radiology, and vascular surgery despite the movement of some diagnostic procedures to non-invasive modalities like CT and MR. Even as MEDRAD continues to innovate and deliver new products with broader capabilities, there will always be a need for an injector like ProVis.”
MEDRAD’s latest generation injection system for live imaging, the MEDRAD Avanta(R) Fluid Management Injection System, provides fixed or variable flow contrast and saline delivery on-demand, replacing the manual manifold and syringe. By enhancing digital fluoroscopy with operator-controlled contrast injections, workflow is improved and contrast consumption is reduced.
Robert Schwartz, M.D., medical director, Abbot Northwestern, Minneapolis Heart Institute Foundation, explained the appeal of a system like MEDRAD Avanta. “The words are control and safety. I have control of what I am putting into the coronary artery, in terms of how much, and how fast of an injection. I’ve got feedback. I can minimize contrast, tailor the dose and save money, but it’s about control and safety.”
Physicians have traditionally used Angiography injectors to inject contrast media into the arterial system of a patient through a catheter to help them see and diagnose vascular disease. While non-invasive modalities are rapidly becoming preferred for diagnosis, Angiography injectors are fundamentally necessary to perform “live imaging” during therapeutic interventions such as angioplasty or the placement of stents. Live imaging refers to the practice of visualizing the arterial system in real-time during a procedure rather than scanning a patient and later reviewing the visuals as is required for non-invasive diagnostic modalities.
MEDRAD, INC. is a worldwide leading provider of medical devices and services that enable and enhance imaging procedures of the human body. Used in diagnostic imaging, MEDRAD’s product offerings include a comprehensive line of vascular injection systems, magnetic resonance (MR) surface coils and patient care products, and equipment services. Total 2006 revenues were $478 million. MEDRAD is a 2003 recipient of the Malcolm Baldrige National Quality Award, the top honor a U.S. company can receive for quality and business excellence. The company’s world headquarters is near Pittsburgh, Pennsylvania, in the United States. MEDRAD is an affiliate of Bayer AG. More company information is available at www.medrad.com.
The Bayer Group is a global enterprise with core competencies in the fields of healthcare, nutrition and high-tech materials. Bayer HealthCare, a subsidiary of Bayer AG, is one of the world’s leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Diabetes Care and Pharmaceuticals divisions. The pharmaceuticals business operates under the name Bayer Schering Pharma AG. Bayer HealthCare’s aim is to discover and manufacture products that will improve human and animal health worldwide. Find more information at www.bayerhealthcare.com.
Cautionary statement regarding forward-looking statements.
Certain statements in this press release that are neither reported financial results nor other historical information are forward-looking statements, including but not limited to, statements that are predictions of or indicate future events, trends, plans or objectives. Undue reliance should not be placed on such statements because, by their nature, they are subject to known and unknown risks and uncertainties and can be affected by other factors that could cause actual results and MEDRAD’s plans and objectives to differ materially from those expressed or implied in the forward-looking statements. MEDRAD, INC. undertakes no obligation to update publicly or revise any of these forward-looking statements, whether to reflect new information or future events or circumstances or otherwise.
For additional information contact: Travis Deschamps MEDRAD Cardiovascular Business Unit 412-767-2400 ext. 3412 Email Contact Dan Dieter MEDRAD Marketing Services 724-940-6949 Email Contact
SOURCE: MEDRAD, INC.
Comments